

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128559 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) A61F 11/20 (2022.01)
C07K 14/47 (2006.01) A61B 5/12 (2006.01)
A61P 27/16 (2006.01)

(21) International Application Number:

PCT/US2024/059365

(22) International Filing Date:

10 December 2024 (10.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/608,803 11 December 2023 (11.12.2023) US
63/549,424 02 February 2024 (02.02.2024) US

(71) Applicant: AKOUOS, INC. [US/US]; 645 Summer Street,
Suite 200, Boston, Massachusetts 02210 (US).

(72) Inventors: WELLMAN, Jennifer; c/o Akouos, Inc., 645
Summer Street, Suite 200, Boston, Massachusetts 02210
(US). SIMONS, Emmanuel John; c/o Akouos, Inc., 645
Summer Street, Suite 200, Boston, Massachusetts 02210
(US). VALERO, Michelle; c/o Akouos, Inc., 645 Sum-
mer Street, Suite 200, Boston, Massachusetts 02210 (US).
SEWELL, William; c/o Akouos, Inc., 645 Summer Street,
Suite 200, Boston, Massachusetts 02210 (US). HICKOX,
Ann; c/o Akouos, Inc., 645 Summer Street, Suite 200,
Boston, Massachusetts 02210 (US). NG, Robert; c/o Ak-
ouos, Inc., 645 Summer Street, Suite 200, Massa-
chusetts 02210 (US).

(74) Agent: NANNENGA-COMBS, Bonnie W. et al.; Sterne,
Kessler, Goldstein & Fox P.L.L.C., 1101 K Street NW, 10th
Floor, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))



WO 2025/128559 A1

(54) Title: COMPOSITIONS AND METHODS FOR TREATING HEARING LOSS IN A HUMAN SUBJECT HAVING A DEFEC-
TIVE OTOFERLIN GENE

(57) Abstract: Provided herein are composition comprising a) a first recombinant adeno-associated viral (rAAV) vector genome com-
prising a first expression cassette comprising a promoter operably linked to nucleic acid sequence comprising a 5' portion of an otoferlin
gene, wherein the first expression cassette is flanked by inverted terminal repeats (ITRs); and b) a second rAAV vector genome
comprising a second expression cassette comprising a nucleic acid sequence comprising a 3' portion of an otoferlin gene, wherein the
second expression cassette is flanked by ITRs, and wherein the composition can comprise about 4E10-9E13 vg/mL, optionally about
about 4.1E10- 4.1E12 total vg or about 8.1E10-8.1E12 total vg and the use of these compositions to treat hearing loss in a subject.